Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Posted 2 years ago

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing’s disease. Patients with Cushing’s disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.

  • Inclusion Criteria : Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No
    • Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option
    • Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry
  • Exclusion Criteria :
    • Patients with ectopic ACTH-dependent Cushing's syndrome
    • Patients with adrenal Cushing's syndrome
    • Patients with Pseudo Cushing's syndrome
  • Study end date : 01/05/2024
Contact details

Southampton, United Kingdom, SO16 6YD

No post found